- Sales amounted to SEK 162 (119) million, corresponding to an increase of 36 percent in SEK. Sales growth was 19 percent in local currency. The acquisition of Unisense FertiliTech A/S contributed SEK 22 million to sales. Adjusted for this, sales growth amounted to 4 percent in local currency.
- Operating income before depreciation and amortization (EBITDA) amounted to SEK 54 (36) million, corresponding to a margin of 33 (31) percent. Fluctuations in exchange rates had a positive effect of SEK 12 million on operating income before depreciation and amortization (EBITDA).
- Net income amounted to SEK 35 (22) million, which gave earnings per share of SEK 1.61 (1.12).
Gothenburg, April 28, 2015
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 28, 2015 at 08:00 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.